Lupus nephritis is an important cause of morbidity and mortality in patients with systemic lupus erythematosus. Traditional outcome criteria such as doubling of serum creatinine, end stage renal disease and death have been used in controlled therapeutic trials, but are limited by their low incidence and the extended period of time required to reach them. More recently, discussions have focused on composite outcome measures, such as remission and relapse, as well as measures of health related quality of life, general lupus activity and cumulative damage indexes. We review the strengths and weaknesses of several outcome criteria, and we propose criteria for both small pilot studies and large definitive trials.
Pollak VE , Pirani CL , Kark RM . Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulo nephritis . J Lab Clin Med1961; 57: 495–511 .
2.
Strand V et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol (in press).
3.
Smolen JS et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol (in press).
4.
Donadio JV Jr et al. A controlled trial of fish oil in IgA nephropathy . N Engl J Med1994; 331: 1194–1199 .
5.
Van Yperselede Strihou C . Fish oil for IgA nephropathy?N Engl J Med1994; 331: 1227–1228 .
6.
Donadio JV Jr , Offord KP . Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life table analysis . Am J Kidney Dis1989; 14: 445–451 .
7.
Austin HA et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs . N Engl J Med1986; 314: 614–619 .
8.
Steinberg AD , Steinberg SC . Long term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only . Arthritis Rheum1991; 34: 945–950 .
9.
Balow JE , Boumpas DT , Fessler BJ , Austin HA III . Management of lupus nephritis . Kidney Int1996; 49 (Suppl. 53): 88–92 .
10.
Hebert LA et al. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus . Am J Kidney Dis1995; 26: 432–438 .
11.
Rasoulpour M , Banco L , Laut JM , Burke GS . Inability of communitybased laboratories to identify pathological casts in urine samples . Arch Pediatr Adolesc Med1996; 150: 1291–1204 .
12.
Moroni G et al. ‘Nephritic flares' are predictors of bad long term renal outcome in lupus nephritis . Kidney Int1996; 50: 2047–2053 .
13.
Moroni G et al. Treatment of membranous lupus nephritis . Am J Kidney Dis1998; 31: 681–686 .
14.
Bootsma H et al. Prevention of relapses in systemic lupus erythematosus . Lancet1995; 345: 1595–1599 .
15.
Pillemer SR et al. Lupus nephritis: association between serology and renal biopsy measures . J Rheumatol1988; 15: 284–288 .
16.
Ricker DM et al. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels . Am J Kidney Dis1991; 28: 678–685 .
17.
Balow JE et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis . N Engl J Med1984; 311: 491–495 .
18.
Valeri A et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five year study . Clin Nephrol1994; 42: 71–78 .
19.
Wernick RM et al. Reliability of histologic scoring for lupus nephritis: a community based evaluation . Ann Intern Med1993; 119: 805–811 .
20.
Lewis EJ et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis . N Engl J Med1992; 326: 1373–1379 .
21.
Gourley MF et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Ann Intern Med1996; 125: 549–557 .
22.
Ciruelo E et al. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide . Arthritis Rheum1996; 39: 2028–2034 .
23.
Sloan RP et al. Long term outcome in systemic lupus erythematosus membranous glomerulonephritis . J Am Soc Nephrol1996; 7: 299–305 .
24.
Nachman PH , Hogan SL , Jennette JC , Falk RJ . Treatment response and relapse in antineutrophil cytoplasmic autoantibody associated micro scopic polyangiitis and glomerulonephritis . J Am Soc Nephrol1996; 7: 33–39 .
25.
Donadio JV Jr , Holley KE , Ferguson RH , Ilstrup DM . Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide . N Engl J Med1978; 299: 1151–1155 .
26.
Boumpas DT et al. Controlled trial of pulse methylprednisone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet1992; 340: 741–745 .
27.
Pando JC et al. Rates of renal remission and relapse in lupus nephritis treated with bolus cyclophosphamide . Arthritis Rheum1994; 37: S179-S179 (abstract).
28.
Manzi S et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity . Arthritis Rheum1996; 39: 1178–1188 .
29.
Abrahamowicz M et al. The relationship between disease activity and expert physicians' decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials . J Rheumatol1998; 25: 277–284 .
30.
Gladman D et al. The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus . Arthritis Rheum1996; 39: 363–369 .
31.
Fortin PR , Abrahamowicz M , Danoff D . Small changes in outpatient lupus activity are better detected by clinical instruments than by laboratory tests . J Rheumatol1995; 22: 2078–2083 .
32.
Honkanen E et al. Adhesion molecules and urinary tumor necrosis factor-a in idiopathic membranous glomerulonephritis . Kidney Int1998; 53: 909–917 .
33.
Yokoyama H et al. Urinary levels of chemokines (MCAF/MCP-1, IL 8) reflect distinct disease activities and phases of human IgA nephropathy . J Leukoc Biol1998; 63: 493–499 .
34.
Domingues GCS et al. Transforming growth factor beta (TGF-beta) activity in urine of patients with glomerulonephritis is related to their renal functional structural changes . Nephrology1998; 4: 31–35 .
35.
Honkanen E et al. Urinary transforming growth factor-b1in membranous glomerulonephritis . Nephrol Dial Transplant1997; 12: 2562–2568 .
36.
Akiyama K et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis . Res Commun Mol Pathol Pharmacol1997; 95: 115–128 .
37.
Illei GG et al. Renal flares in patients with proliferative lupus nephritis treated with immunosuppressive therapy: classification, prevalence and outcomes . Arthritis Rheum1998; 41: S242-S242 (Abstract).
